Spinal Muscular Atrophy Treatment and Outcomes
This webinar will provide an overview of U.S. Food and Drug Administration (FDA) approved therapies for SMA, the pros and cons of each therapy, physician's experiences with these therapies, and long-term issues regarding treatment and outcomes. Please note that the purpose of this webinar is strictly for information dissemination and discussion; APHL does not endorse any specific therapy or treatment.
Audience: Individuals responsible for screening, diagnosing and treating SMA.
Moderators: Amy Gaviglio, MS, LCGC, Co-Chair, APHL NewSTEPs New Disorders Workgroup
George Dizikes, PhD, HCLD/CC (ABB), Co-Chair, APHL NewSTEPs New Disorders Workgroup
Jennifer M. Kwon, MD, CGC, Faculty, University of Wisconsin School of Medicine and Public Health
Russell Butterfield, MD, PhD, Department of Neurology and Pediactrics, University of Utah
Melissa A. Gibbons, MS, CGC, Genetic Councelor, Children's Hospital Colorado
Julie Parsons, MD, Co-Director, Neuromuscular Clinic, Children's Hospital Colorado